Factors associated with pregnancy outcomes in women with a history of cerebral sinus venous thrombosis.


Journal

Journal of thrombosis and thrombolysis
ISSN: 1573-742X
Titre abrégé: J Thromb Thrombolysis
Pays: Netherlands
ID NLM: 9502018

Informations de publication

Date de publication:
Jul 2020
Historique:
pubmed: 28 10 2019
medline: 10 4 2021
entrez: 28 10 2019
Statut: ppublish

Résumé

To collect and summarize pregnancy outcomes among women with a history of cerebral sinus vein thrombosis (CSVT). A retrospective multicenter case-control study. The study group comprised all women diagnosed with CSVT during 2004-2018 at four university hospitals, and with follow-up data of pregnancy. A control group of women with a singleton pregnancy was established by matching, four-to-one, according to maternal age. The data of 74 pregnancies of 65 women with CSVT were analyzed. The median time-to-pregnancy interval from the CSVT was 4.2 [2.7-6.8] years. Anticoagulation therapy in the form of enoxaparin was administered in 68 (91.9%) pregnancies. Adjunctive low-dose aspirin was used throughout 12 (16.2%) pregnancies. Overall, 54 (73.0%) of the pregnancies ended in live births and 20 (27.0%) in miscarriage. The use of anticoagulation therapy during pregnancy was positively associated with live birth outcome (P < 0.001). Late adverse outcomes were encountered in 19 (25.7%) pregnancies, including the delivery of a small for gestational age infant (n = 12), gestational hypertensive disorders (n = 6) and placental abruption (n = 3). The use of adjunctive aspirin was associated with a lower rate of late adverse pregnancy outcomes (P = 0.03). No recurrent CSVT, thrombosis at other sites, and major bleeding episodes were observed during pregnancy. Live-birth rate was higher (P = 0.007) and the rate of late adverse outcome was lower (P = 0.01) for the control (n = 296) than the study group. Among pregnant women with a prior CSVT, no recurrent thrombosis events were observed during gestation. The use of prophylactic anticoagulation was associated with live birth. The use of adjunctive aspirin should be further studied in this setting, as its utilization correlated with a lower rate of late pregnancy complications.

Identifiants

pubmed: 31655969
doi: 10.1007/s11239-019-01978-8
pii: 10.1007/s11239-019-01978-8
doi:

Substances chimiques

Anticoagulants 0
Enoxaparin 0

Types de publication

Journal Article Multicenter Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

151-156

Références

Bousser MG, Ferro JM (2007) Cerebral venous thrombosis: an update. Lancet Neurol 6:162–170
doi: 10.1016/S1474-4422(07)70029-7 pubmed: 17239803
Stam J (2005) Thrombosis of the cerebral veins and sinuses. N Engl J Med 352:1791–1798
doi: 10.1056/NEJMra042354 pubmed: 15858188
Ciron J, Godenèche G, Vandamme X, Rosier MP, Sharov I, Mathis S et al (2013) Obstetrical outcome of young women with a past history of cerebral venous thrombosis. Cerebrovasc Dis 36(1):55–61
doi: 10.1159/000351507 pubmed: 23921093
Martinelli I, Passamonti SM, Maino A, Abbattista M, Bucciarelli P, Somigliana E et al (2016) Pregnancy outcome after a first episode of cerebral vein thrombosis. J Thromb Haemost 14(12):2386–2393
doi: 10.1111/jth.13496 pubmed: 27598406
de Sousa DA, Canhão P, Ferro JM (2016) Safety of pregnancy after cerebral venous thrombosis: a systematic review. Stroke 47:713–718
doi: 10.1161/STROKEAHA.115.011955
Poli D, Cenci C, Testa S, Paoletti O, Silvestri E, Antonucci E (2017) Obstetrical history of women with cerebral vein thrombosis: outcome of the pregnancies before and after the thrombotic event. Intern Emerg Med 12(7):941–945
doi: 10.1007/s11739-017-1682-0 pubmed: 28589438
de Sousa DA, Canhão P, Crassard I, Coutinho J, Arauz A, Conforto A et al (2017) Safety of pregnancy after cerebral venous thrombosis: results of the ISCVT (International Study on Cerebral Vein and Dural Sinus Thrombosis)-2 PREGNANCY Study. Stroke 48:3130–3133
doi: 10.1161/STROKEAHA.117.018829
de Sousa DA, Canhão P, Ferro JM (2018) Safety of pregnancy after cerebral venous thrombosis: systematic review update. J Neurol 265(1):211–212
doi: 10.1007/s00415-017-8666-x
Dollberg S, Haklai Z, Mimouni FB, Gorfein I, Gordon ES (2005) Birth weight standards in the live-born population in Israel. Isr Med Assoc J 7:311–314
pubmed: 15909464
Ventura SJ, Curtin SC, Abma JC, Henshaw SK (2012) Estimated pregnancy rates and rates of pregnancy outcomes for the United States, 1990–2008. Natl Vital Stat Rep 60:1–21
pubmed: 22970648
Rodger MA, Gris JC, de Vries JIP, Martinelli I, Rey É, Schleussner E et al (2016) Low-molecular-weight heparin and recurrent placenta-mediated pregnancy complications: a meta-analysis of individual patient data from randomised controlled trials. Lancet 388(10060):2629–2641
doi: 10.1016/S0140-6736(16)31139-4 pubmed: 27720497
Rolnik DL, Wright D, Poon LC, O’Gorman N, Syngelaki A, de Paco Matallana C et al (2017) Aspirin versus placebo in pregnancies at high risk for preterm preeclampsia. N Engl J Med 377(7):613–622
doi: 10.1056/NEJMoa1704559 pubmed: 28657417
Tan MY, Poon LC, Rolnik DL, Syngelaki A, de Paco Matallana C, Akolekar R et al (2018) Prediction and prevention of small-for-gestational-age neonates: evidence from SPREE and ASPRE. Ultrasound Obstet Gynecol 52(1):52–59
doi: 10.1002/uog.19077 pubmed: 29704277
Miranda B, Ferro JM, Canhao P, Stam J, Bousser MG, Barinagarrementeria F et al (2010) Venous thromboembolic events after cerebral vein thrombosis. Stroke 41(9):1901–1906
doi: 10.1161/STROKEAHA.110.581223 pubmed: 20634477
Martinelli I, Bucciarelli P, Passamonti SM, Battaglioli T, Previtali E, Mannucci PM (2010) Long-term evaluation of the risk of recurrence after cerebral sinus-venous thrombosis. Circulation 121(25):2740–2746
doi: 10.1161/CIRCULATIONAHA.109.927046 pubmed: 20547928
Gosk-Bierska I, Wysokinski W, Brown RD Jr, Karnicki K, Grill D, Wiste H et al (2006) Cerebral venous sinus thrombosis: incidence of venous thrombosis recurrence and survival. Neurology 67(5):814–819
doi: 10.1212/01.wnl.0000233887.17638.d0 pubmed: 16966543
Saposnik G, Barinagarrementeria F, Brown RD Jr, Bushnell CD, Cucchiara B, Cushman M, deVeber G, Ferro JM, Tsai FY (2011) American Heart Association Stroke Council and the Council on Epidemiology and Prevention: diagnosis and management of cerebral venous thrombosis: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 42:1158–1192
doi: 10.1161/STR.0b013e31820a8364 pubmed: 21293023
Greer IA, Nelson Piercy C (2005) Low molecular weight heparins for thromboprophylaxis and treatment of venous thromboembolism in pregnancy: a systematic review of safety and efficacy. Blood 106:401–407
doi: 10.1182/blood-2005-02-0626 pubmed: 15811953
Cox S, Eslick R, McLintock C (2019) Effectiveness and safety of thromboprophylaxis with enoxaparin for prevention of pregnancy-associated venous thromboembolism. J Thromb Haemost 17(7):1160–1170
doi: 10.1111/jth.14452 pubmed: 31013386
Duley L, Henderson-Smart DJ, Meher S, King JF (2007) Antiplatelet agents for preventing pre-eclampsia and its complications. Cochrane Database Syst Rev 2:CD004659
Askie LM, Duley L, Henderson-Smart DJ, Stewart LA (2007) Antiplatelet agents for prevention of pre-eclampsia: a meta-analysis of individual patient data PARIS Collaborative Group. Lancet 369:1791–1798
doi: 10.1016/S0140-6736(07)60712-0 pubmed: 17512048
Henderson JT, Whitlock EP, O’Connor E, Senger CA, Thompson JH, Rowland MG (2014) Low-dose aspirin for prevention of morbidity and mortality from preeclampsia: a systematic evidence review for the U.S. Preventive Services Task Force. Ann Intern Med 160:695–703
doi: 10.7326/M13-2844 pubmed: 24711050
Ahrens KA, Silver RM, Mumford SL, Sjaarda LA, Perkins NJ, Wactawski-Wende J et al (2016) Complications and safety of preconception low-dose aspirin among women with prior pregnancy losses. Obstet Gynecol 127:689–698
doi: 10.1097/AOG.0000000000001301 pubmed: 26959198 pmcid: 4805457
Committee ACOG (2018) ACOG Committee Opinion No 743: low-dose aspirin use during pregnancy. Obstet Gynecol 132(1):e44–e52
doi: 10.1097/AOG.0000000000002708

Auteurs

Amihai Rottenstreich (A)

Department of Obstetrics and Gynecology, Hadassah-Hebrew University Medical Center, Jerusalem, Israel.

Harel Gershgoren (H)

Faculty of Medicine, Hadassah-Hebrew University Medical Center, Jerusalem, Israel.

Galia Spectre (G)

Department of Hematology, Coagulation Unit, Beilinson Hospital, Rabin Medical Center, Petah Tikva, Israel.
Sackler Faculty of Medicine, Tel-Aviv University, Tel Aviv, Israel.

Nael Da'as (N)

Internal Medicine D, Hematology Unit, Shaare Zedek Medical Center, Jerusalem, Israel.

Ohad S Bentur (OS)

Sackler Faculty of Medicine, Tel-Aviv University, Tel Aviv, Israel.
Division of Hematology, Sourasky Medical Center, Tel Aviv, Israel.

Gabriel Levin (G)

Department of Obstetrics and Gynecology, Hadassah-Hebrew University Medical Center, Jerusalem, Israel.

Yosef Kalish (Y)

Department of Hematology, Hadassah-Hebrew University Medical Center, POB 12000, 91120, Jerusalem, Israel. ykalish@gmail.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH